LOGIN
Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19
March 2021
Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Lancet. 2021 Feb 13;397(10274): 605-612.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Of the 9433 patients participating in the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, 7763 were randomized to receive azithromycin plus standard care (n=2582), or standard care alone (n=5181; 837 eventually crossed over to receive azithromycin or tocilizumab but were still included in the analysis). The primary outcome of interest was all-cause mortality at 28 days. Secondary outco...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.